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April 15, 2016; doi:10.1152/ajplung.00288.2015.—Toll-like receptor
(TLR) 7 agonists are known to reduce allergic airway inflammation.
Their recently reported ability to rapidly relax airways has further
increased their interest in the treatment of pulmonary disease. How-
ever, the mechanisms behind this effect are not fully understood. The
present study, therefore, aimed to determine whether airway smooth
muscle (ASM)-dependent mechanisms could be identified. TLR7
agonists were added to guinea pig airways following precontraction
with carbachol in vitro or histamine in vivo. Pharmacological inhib-
itors were used to dissect conventional pathways of bronchodilation;
tetrodotoxin was used or bilateral vagotomy was performed to assess
neuronal involvement. Human ASM cells (HASMCs) were employed
to determine the effect of TLR7 agonists on intracellular Ca2
([Ca2]i) mobilization. The well-established TLR7 agonist imi-
quimod rapidly relaxed precontracted airways in vitro and in vivo.
This relaxation was demonstrated to be independent of nitric oxide,
carbon monoxide, and cAMP signaling, as well as neuronal activity.
A limited role for prostanoids could be detected. Imiquimod induced
[Ca2]i release from endoplasmic reticulum stores in HASMCs,
inhibiting histamine-induced [Ca2]i. The TLR7 antagonist IRS661
failed to inhibit relaxation, and the structurally dissimilar agonist
CL264 did not relax airways or inhibit [Ca2]i. This study shows that
imiquimod acts directly on ASM to induce bronchorelaxation, via a
TLR7-independent release of [Ca2]i. The effect is paralleled by other
bronchorelaxant compounds, like chloroquine, which, like imi-
quimod, but unlike CL264, contains the chemical structure quinoline.
Compounds with quinoline moieties may be of interest in the devel-
opment of multifunctional drugs to treat pulmonary disease.
asthma; bronchodilation; imiquimod; quinoline; toll-like receptor 7
TOLL-LIKE RECEPTOR (TLR) AGONISTS have recently become of
interest as novel therapeutic targets for the treatment of allergy
and asthma (2). TLRs, which are a subset of virus- and
bacteria-sensing, pathogen-recognition receptors, are pivotal
for the early response against infection. Activation results in an
immediate production of proinflammatory cytokines (23), and,
most commonly, development of a Th1 response.
Treatment with TLR agonists, alone or as adjuvants in
allergen-specific immunotherapy (34), has been shown to mod-
ify and dampen the allergic inflammatory response (2, 8). In
particular, treatment with agonists of TLR7, which recognizes
viral single-stranded RNA, results in a reduction in Th2 cyto-
kine levels, eosinophilia, goblet cell hyperplasia, and total IgE
levels (3, 17, 21, 37, 38), as well as airway hyperresponsive-
ness in vivo (1) and airway reactivity following long-term
culture in vitro (12). In the clinic, TLR7 agonists have proved
effective in the treatment of seasonal allergic rhinitis (16).
TLR7 agonists are of particular interest as novel studies have
demonstrated that the prototypical agonist imiquimod (R-837)
also harbors the ability to induce rapid airway relaxations in
vitro, as well as in vivo (11, 22). This further highlights a role
for the use of these agonists in the treatment of asthma. To
date, relaxation has primarily been attributed to a TLR7-
dependent release of neuronally derived nitric oxide (NO), but
other additional mechanisms must be considered. The present
study was designed to characterize this in depth.
MATERIALS AND METHODS
Animals. Male Dunkin-Hartley guinea pigs (250–750 g) were
obtained from Harlan (Horst, The Netherlands). They were housed in
groups of five in plastic cages with adsorbent bedding in temperature
and light-dark cycle (12:12 h) controlled rooms. Food and water were
available ad libitum.
Animals were handled in accordance with the Federation for
European Laboratory Animal Science Associations guidelines. All
animal procedures were approved by the local ethics committee at
Karolinska Institutet (Stockholm norra djurförsöksetiska nämnd; eth-
ical permit nos.: N44-12, N41-14, and N143-14). In total, 60 animals
were used for this study.
In vitro pharmacology. Organ bath experiments with guinea pig
trachea were performed as described previously (32, 33). Animals
were killed by CO2 or an overdose of pentobarbital sodium (Apoteket,
Stockholm, Sweden). The trachea was quickly removed and dissected
free of surrounding connective tissue in Krebs-Henseleit buffer solu-
tion (composition in mM: NaCl 118.5, KCl 4.7, KH2PO4 1.2, MgCl2
1.2, CaCl2 2.5, NaHCO3 25, and D-glucose 11.1). Tracheal segments
were cut along the cartilage into eight rings of equal length and
mounted in 5-ml organ baths [or myographs for electric field stimu-
lation (EFS) experiments] filled with Krebs-Henseleit buffer solution
at 37°C, bubbled with carbon gas (5% CO2 in O2). Changes in smooth
muscle force were detected using an isometric force-displacement
transducer linked to a Grass polygraph. For denudation experiments,
epithelium was removed by mechanical scraping with a scalpel and
confirmed via microscopy.
Segments were equilibrated for 60 min, where the force was
adjusted to 30 mN. Tracheal reactivity was assessed through the
cumulative addition of histamine (0.1 nM to 0.1 mM), and, after a
30-min wash-out period, further pharmacological studies were con-
ducted. Tracheal rings were precontracted with carbachol (100 nM).
Once stable precontractions were obtained, segments were exposed to
cumulative concentrations of imiquimod (0.1–100 M; Invivogen,
San Diego, CA), R-848 (0.1–300 M; Invivogen), CL-264 (0.1–300
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M; Invivogen), salbutamol (0.1–1,000 nM), or vehicle. At the end of
each experiment, maximal relaxations were assessed for each individ-
ual segment through the administration of papavarine (100 M) and
sodium nitroprusside (100 M). For EFS experiments, segments were
equilibrated, force was adjusted, and reactivity was assessed as above.
Segments were exposed to indomethacin (3 M) and atropine (1 M)
for 30–40 min and subsequently exposed to histamine (1 M) until a
stable contraction was obtained. Electrodes delivering electrical stim-
ulation were placed on opposite sides of the segments (Current
Stimulator model CS200, J.P. Trading, Aarhus, Denmark). Three
consecutive 60-s stimulations (16.0 Hz, 55 mA, 1.0-ms pulse dura-
tion) were given 150 s apart, to induce reversible tracheal relaxation.
In vivo studies. Guinea pigs were ventilated with a flexiVent animal
ventilator (Scireq, Montreal, Quebec, Canada). Following anesthesia
with fentanyl (500 g/kg ip), midazolam (30 mg/kg ip), and droperi-
dol (5 mg/kg ip) (all Apoteket), animals were placed on a heating pad
(37°C), tracheotomized, and connected to the ventilator via a 16-
gauge (2.1 mm) cannula. Guinea pigs were given repeated doses of
anesthetic, at 50% of the original dose, every 40 min. Pulse and SO2
levels remained stable throughout the experiment. Airways were
precontracted with a continuous infusion of histamine (7.5–12.5
g·kg1min1 iv), to produce an approximate fivefold increase in the
basal lung resistance. Once a stable baseline had been reached,
aerosolized distilled water (dH2O) or imiquimod was given. In con-
centration-response experiments, increasing concentrations of imi-
quimod were given noncumulatively. A stable baseline of contraction
was recovered before treatment with the subsequent concentration of
imiquimod. For vagotomy experiments, animals were bilaterally va-
gotomized before infusion of histamine.
In vitro and in vivo pharmacological interventions. The pharma-
cological interventions NG-nitro-L-arginine methyl ester (L-NAME;
100 M in vitro, 30 mg/kg in vivo) and NG-monomethyl-L-arginine
(L-NMMA; 100 M) were used to study the involvement of NO;
tetrodotoxin (TTX; 1 M) was used to study the involvement of
neurons; KT-5823 (1 M), Rp-8-Br-PET-cGMPS (0.1 mg/kg iv), H89
(10 M), and zinc protoporphyrin IX (ZnPP9; 30 M) were given to
study the involvement of protein kinase G (PKG), cyclic guanine
monophosphate (cGMP), protein kinase A (PKA), and carbon mon-
oxide (CO); and the TLR7 antagonist IRS661 (100 m in vitro, 0.2
mg/kg iv in vivo) was used to study the involvement of TLR7. In
vitro, L-NAME and L-NMMA were administered on established
precontractions, 30 min before imiquimod administration; TTX was
administered 30 min before precontraction; KT-5823 and H89 were
administered 30 min before the precontractions; ZnPP9 was admin-
istered 30 min before precontractions or acutely; and IRS661 was
administered 1 h before the induction of precontractions. As the level
of precontraction has been shown to affect the response to different
bronchorelaxants (e.g., salbutamol), precontractions were adjusted to
50–60% of the reference maximal contractions of the individual
rings. Except for studies using indomethacin, all in vitro pharmaco-
logical interventions were performed in the presence of EP1 receptor
antagonist ONO-8130 (100 nM), which prevents prostanoid-induced
modulation of contractile and relaxing responses (33). In vivo, L-
NAME was administered 30 min before imiquimod treatment; Rp-8-
Br-PET-cGMPS was administered 0, 15, 30, and 45 min before
imiquimod; and IRS661 was administered 60, 90, or 120 min before
imiquimod. Stable histamine-induced precontractions were estab-
lished, and the response to imiquimod was assessed before adminis-
tration of pharmacological agents. In all experiments using pharma-
cological interventions in vivo, imiquimod was administered at a
concentration of 3 mg/ml.
Measurement of Ca2 flux in human airway smooth muscle cells.
Primary bronchial human airway smooth muscle cells (HASMCs)
were obtained from Promocell (Heidelberg, Germany). Cells from
four separate patients were used, between passages 4 and 6. Cells
were cultured in smooth muscle cell growth medium supplemented
with 5% fetal calf serum, 0.5 ng/ml epidermal growth factor, 2 ng/ml
basic fibroblast growth factor, 5 g/ml insulin, 100 U/ml penicillin,
100 g/ml streptomycin (Gibco, NY), and 0.25 g/ml Fungizone
(Gibco); they were maintained in a humidified chamber at 37°C with
a constant supply of 5% CO2. Media and supplements were obtained
from Promocell, unless otherwise specified. Before experiments, cells
were growth arrested with serum-free media for 24 h. Cells were
stained with the calcium indicator fluo 4-AM (3 M, Molecular
Probes, Invitrogen, San Diego, CA), and changes in mean fluores-
cence intensity over time were detected on an BD Accuri C6 Flow
Cytometer (BD, San Jose, CA). Analysis was performed with FlowJo
software (Tree Star, Ashland, OR). In experimental setup 1, following
a 30-s baseline recording of Ca2 fluxes, cells were exposed to
imiquimod (100 M) or histamine (100 M). In experimental setup 2,
cells were pretreated with thapsigargin (1 M) or dH2O for 30 min.
Following a 60-s baseline recording of Ca2 fluxes, cells were
exposed to imiquimod (100 M). In experimental setup 3, Ca2
fluxes were continuously monitored. At 60 s, cells were exposed to
imiquimod (100 M) or dH2O. At 300 s, cells were exposed to
thapsigargin (1 M). In experimental setup 4, cells were preincubated
with different concentrations of imiquimod, CL264 (10, 30, or 100
M), or vehicle for 5 min. Following a 30-s baseline recording of
Ca2 fluxes, cells were exposed to histamine (100 M).
Drugs and materials. NaCl, KCl, KH2PO4, MgCl2, CaCl2,
NaHCO3, and D-glucose were purchased from VWR (West Chester,
PA). Carbachol, histamine, salbutamol, papavarine, sodium nitroprus-
side, L-NAME, L-NMMA, Rp-8-Br-PET-cGMPS, indomethacin, and
IRS661 were purchased from Sigma Aldrich (St. Louis, MO). Imi-
quimod, R-848, and CL-264 were purchased from Invivogen. KT-
5823, H89, thapsigargin, and TTX were purchased from Tocris
Bioscience (Bristol, UK). ONO-8130 was a kind gift from ONO
Pharmaceuticals (Japan).
Statistics. Data was analyzed using GraphPad Prism 6 Software
(San Diego, CA). All results are presented as means  SE. For in vitro
pharmacology experiments, the concentration-response curve values
for pEC50 and Emax were calculated using nonlinear regression anal-
ysis. EC50 values were compared using Student’s t-test. In vivo and
Ca2 mobilization experiments were analyzed using a one-way or a
two-way ANOVA (vagotomy), followed by Bonferroni post hoc tests.
RESULTS
Imiquimod relaxes precontracted guinea pig airways in vitro
and in vivo. Cumulative addition of imiquimod in vitro resulted
in concentration-dependent and rapid complete relaxation of
tracheal rings precontracted with carbachol (Fig. 1A, pEC50 
4.46  0.05, EC50  34.8 M), verifying previously published
results (22).
For in vivo studies, continuous intravenous infusion of
histamine resulted in a stable and reproducible contraction
40–50 min after the start of infusion. Challenge with aerosol-
ized imiquimod (0.3–30 mg/ml) resulted in a concentration-
dependent relaxation of contraction, as measured by a reduc-
tion in Newtonian resistance (RN; an approximation of resis-
tance in the conducting airways, Fig. 1B, P  0.0001) and
tissue resistance (G; which reflects energy dissipation in pe-
ripheral lung tissue, Fig. 1C, P  0.0001). A similar trend was
evident for tissue elastance (H, a reflection of tissue stiffness in
peripheral lung tissue), but did not reach significance (data not
shown). Relaxation occurred within 10 s of administration;
contraction returned to baseline levels after 10–15 min.
Administration of imiquimod alone had no effect on baseline
in vitro or in vivo (data not shown).
Imiquimod relaxes precontracted guinea pig airways inde-
pendently of the epithelium. The tracheal epithelium is known
to release mediators involved in bronchodilation. In this light,
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we assessed whether the epithelium was necessary for imi-
quimod-mediated relaxation. However, denudation of the tra-
cheal epithelium had no significant effect on imiquimod-med-
itated relaxation (Table 1).
Imiquimod relaxes precontracted guinea pig airways inde-
pendently of conventional pathways of bronchodilation. Using
our in vitro and in vivo models, we next examined molecules
and associated signaling pathways involved in bronchodilation,
including the role of NO and prostanoids, previously impli-
cated in imiquimod-mediated bronchodilation (11, 22), CO,
cGMP, PKG, and PKA.
Administration of indomethacin before imiquimod adminis-
tration in vitro resulted in a small, but significant, decrease in
potency (Table 1, P  0.021), compared with administration of
vehicle, which is in accordance with previous observations
(22). Comparatively, exposure to L-NAME, L-NMMA (NO
synthase inhibitors; Fig. 2A, Table 1), ZnPP9 [heme oxygenase
1 (HO-1) inhibitor], and KT-5823 (PKG inhibitor, Fig. 2B,
Table 1) did not significantly alter imiquimod-mediated relax-
ation. Administration of H89 (PKA inhibitor) significantly
reduced the potency of salbutamol-mediated relaxation (P 
0.014), but had no effect on imiquimod-mediated relaxation of
precontracted guinea pig airways in vitro (Table 1).
Intravenous administration of L-NAME in vivo resulted in a
small, nonsignificant trend (P  0.08) toward a reversal of
imiquimod (3 mg/ml)-induced reduction in RN, but had no
effect on G (Fig. 3, A and B). Rp-8-Br-PET-cGMPS (cGMP
synthase inhibitor) had no effect on imiquimod-mediated re-
duction in RN or G, when given before imiquimod (Fig. 3, C
and D).
Imiquimod relaxes precontracted guinea pig airways in vivo
and in vitro, independently of central and peripheral neurons.
Bilateral vagotomy was performed to determine the involve-
ment of central neuronal reflexes on relaxation in vivo. Hista-
mine-induced increases in RN and G were unaffected by
vagotomy (data not shown). There was no significant differ-


























































Fig. 1. Imiquimod (IMQ) relaxes precon-
tracted guinea pig airways in vitro and in
vivo. A: tracheal rings were precontracted
with carbachol (CCH) in vitro. Increasing
doses of IMQ were added cumulatively, and
percent change from maximum contraction
was determined (n  12–26). Values are
mean percentage of maximal contraction 
SE. B and C: guinea pig airways were pre-
contracted with intravenous histamine in
vivo. Aerosolized IMQ was added noncumu-
latively, and changes in maximal Newtonian
resistance (RN; B) and tissue resistance (G; C)
were determined. Values are mean percentage
of maximal resistance  SE. P  0.05 vs.
a|vehicle, b|0.3 mg/ml, c|1.5 mg/ml, and d|3
mg/ml using one-way ANOVA, followed by
a Bonferroni post hoc test (n  7–18).
Table 1. Relaxation of precontracted guinea pig tracheal rings following incubation with inhibitors of endogenous
bronchodilatory mediators
Bronchorelaxant Signaling Molecule Intervention pEC50  SE (Vehicle) pEC50  SE (Inhibitor) P Value (Vehicle vs. Inhibitor) n
Imiquimod Epithelium Denudation 4.5  0.06 4.6  0.03 0.33 (ns) 8
COX-1/2 Indomethacin 4.6  0.02 4.4  0.07 0.02* 5
NOS L-NAME 4.3  0.11 4.3  0.28 0.51 (ns) 4
L-NMMA 4.3  0.11 4.3  0.11 0.99 (ns) 4
HO-1 ZnPP9 4.5  0.14 4.5  0.08 0.41 (ns) 4
PKG KT-5823 4.5  0.14 4.4  0.07 0.59 (ns) 4
PKA H89 4.6  0.15 4.7  0.11 0.58 (ns) 4
Neuron TTX 4.5  0.06 4.6  0.06 0.60 (ns) 4
n, No. of animals. Guinea pig tracheal rings were precontracted with carbachol and subsequently exposed to imiquimod or salbutamol. COX-1/2,
cyclooxygenase-1/2; NOS, nitric oxide synthase; HO-1, heme oxygenase 1; PKG, protein kinase G; PKA, protein kinase A; TTX, tetrodotoxin; pEC50, log of
effective concentration of 50%; ns, nonsignificant. *Significant difference.
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ence in reduction of RN (Fig. 4A) or G (Fig. 4B) between
vagotomized and sham-vagotomized animals following aero-
solized imiquimod administration, at any of the concentrations
used.
Using our in vitro model, we further assessed if imiquimod-
induced relaxation was dependent on bronchodilatory media-
tors released by inhibitory nonadrenergic, noncholinergic
(iNANC) neuronal fibers, using the neurotoxin TTX. Sensitiv-
ity of iNANC fibers to TTX was first determined using a model
of neuronally mediated bronchodilation. Guinea pig tracheas
were precontracted with histamine; EFS was subsequently
applied to the tracheas in the presence of atropine, to exclude
cholinergic effects. EFS resulted in a rapid and reversible
relaxation of tracheas that was completely inhibited by TTX
(Fig. 4C). Comparatively, pretreatment with TTX had no effect
on imiquimod-induced relaxation (Fig. 4D, Table 1).
Imiquimod induces intracellular Ca2 mobilization and
blocks histamine-induced Ca2 mobilization, in isolated
HASMCs. The effect of imiquimod on intracellular Ca2 mo-
bilization ([Ca2]i) a prerequisite of airway smooth muscle
(ASM) cell contraction, was subsequently measured, as the
data indicated that imiquimod-mediated relaxation was not
mediated by conventional bronchodilatory pathways. Surpris-
ingly, addition of imiquimod to HASMC induced a reproduc-
ible increase in mean fluorescence intensity, an arbitrary mea-
sure of [Ca2]i concentration (Fig. 5A). The increase in [Ca2]i
was significantly higher than that induced by histamine (Fig. 5,
A and B). A similar rise in [Ca2]i following imiquimod
exposure was evident when extracellular calcium was removed
(data not shown). Pretreatment with thapsigargin significantly
blunted the imiquimod-induced rise in [Ca2]i in HASMC
(Fig. 5C); reciprocally, imiquimod inhibited thapsigargin-in-
duced increases in [Ca2]i (Fig. 5D), suggesting the endoplas-
mic reticulum (ER) to be a source of imiquimod-induced
[Ca2]i. To assess if the imiquimod-mediated rise in [Ca2]i
could impact the rise in [Ca2]i following histamine, HASMC
were preincubated with imiquimod for 5 min and subsequently
exposed to histamine. Imiquimod preincubation resulted in a
concentration-dependent reduction in [Ca2]i following addi-
tion of histamine (P  0.004) (Fig. 5, E and F), with a potency


















































Fig. 2. Imiquimod (IMQ) relaxes precon-
tracted guinea pig airways independently of
nitric oxide (NO) and protein kinase G (PKG)
in vitro. Tracheal rings were precontracted
with carbachol (CCH). IMQ was added in the
presence or absence of the NO inhibitors
L-NAME or L-NMMA (A) or the PKG inhib-
itor KT-5823 (B). Values are mean percent-

























































Fig. 3. Imiquimod (IMQ) relaxes precon-
tracted guinea pig airways independently of
nitric oxide (NO) and cGMP in vivo. Guinea
pig airways were precontracted with intrave-
nous histamine in vivo. The NO inhibitor
L-NAME (30 mg/kg; A and B) or the cGMP
inhibitor Rp-8-Br-PET-cGMPS (0.1 mg/kg;
C and D) were given before administration of
aerosolized IMQ (3 mg/kg). Changes in
Newtonian resistance (RN; A and C) and
tissue resistance (G; B and D) were deter-
mined. Values are mean percentage of max-
imal resistance. *P  0.05, ***P  0.001,
****P  0.0001 vs. vehicle using one-way
ANOVA, followed by a Bonferroni post-
hoc test (n  6).
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similar to imiquimod-mediated bronchorelaxation in vitro
(pEC50  4.68  0.08).
Imiquimod-induced relaxation is not dependent on TLR7.
The role of TLR7 on imiquimod-induced airway relaxation
was subsequently examined, using the TLR7 antagonist
IRS661 and other structurally similar and dissimilar TLR7
agonists. Intravenous administration of IRS661 in vivo had no
significant effect on imiquimod-mediated reduction in RN (Fig.
6A) or G (Fig. 6B), when administered before imiquimod.
Similarly, no significant difference in imiquimod-induced re-
laxation in IRS661-treated tracheal rings was found, compared
with control (Fig. 6C).
As reported (22), R-848, a TLR7/8 agonist, and imidazo-
quinoline, with a similar chemical structure to R-837, induced
a concentration-dependent relaxation of tracheal rings precon-
tracted with carbachol, but with a lower potency. The struc-
turally dissimilar TLR7 agonist CL264 (19) is a more potent
activator of TLR7-specific immune events (10) (data not
shown). However, CL264 did not relax precontracted guinea
pig trachea (Fig. 6D) and had no effect on histamine-induced
increases in [Ca2]i (Fig. 6, E and F).
DISCUSSION
TLR7 ligands have shown preclinical and clinical success in
the treatment of allergic disease, due to their ability to modu-
late and reduce allergic airway inflammation (16, 17, 37, 38).
Their recently reported ability to rapidly relax airways (11, 22)
has increased their interest in the treatment of pulmonary
disease. The present study verified the ability for imiquimod to
induce a strong and rapid dilatory effect in isolated guinea pig
airways. It also, for the first time, demonstrated that imiquimod
could directly relax airways precontracted with histamine in
vivo. Epithelial denudation and TTX-mediated blockage of
neuronal release ruled out the involvement of epithelium- or
neuron-derived mediators. In addition, various pharmacologi-
cal inhibitors further dismissed the involvement of traditional
airway dilatory mechanisms, including NO, CO, and cAMP
signaling. Further investigations in isolated ASM cells demon-
strated that imiquimod induced a rise in ER-derived [Ca2]i,
which was associated with an inhibition [Ca2]i following
histamine exposure. Bronchorelaxatory effects were not af-
fected by TLR7 antagonism, and neither relaxation nor Ca2
inhibition were evident in response to the structurally dissim-
ilar TLR7 agonist CL264, signifying that this effect was
independent of TLR7.
To investigate imiquimod-mediated bronchodilation in vivo,
we developed a model based on our laboratory’s previous
studies (5, 6) that allowed extensive evaluation of bronchodi-
lators in guinea pigs in vivo. Animals were anesthetized with a
novel triple combination anesthetic, which ensured stable sur-
gical anesthesia for up to 4 h in ventilated animals. A contin-
uous intravenous infusion of histamine resulted in a stable
airway contraction, enabling the direct measurement of aero-
solized bronchodilatory compounds. Using this in vivo setup,
changes in RN, G, and H could be measured. This approach
allowed the dissection of changes in resistance in relation to
both central (RN) and peripheral (G and H) airways (31).
Decreases in RN, G, and H were evident within seconds
following imiquimod administration, suggesting that imi-
quimod concentration-dependently dilated histamine-precon-
tracted airways in both central and peripheral compartments.
This study is the first to show that imiquimod can reverse
established histamine-induced precontractions in vivo.
To study mechanisms of imiquimod-mediated bronchodila-
tion, we evaluated the effect of epithelial denudation and
pharmacological inhibition of conventional pathways of bron-
chodilation. Removal of the epithelium had no effect on





















































































Fig. 4. Imiquimod (IMQ) relaxes precon-
tracted guinea pig airways independently of
the neuronal pathways. A and B: guinea pig
airways were precontracted with intravenous
histamine in vivo. Before contraction, ani-
mals were bilaterally vagotomized or sham
equivalent. Aerosolized IMQ was given non-
cumulatively, and changes in maximal New-
tonian resistance (RN; A) and tissue resis-
tance (G; B) were determined. Values are
mean percentage of maximal resistance  SE
(n  7–18). Data were analyzed using a
two-way ANOVA, followed by a Bonferroni
post hoc test. C: a representative trace to
show inhibition of electric field stimulation
(EFS)-induced bronchorelaxation with tetro-
dotoxin (TTX). D: tracheal rings were pre-
contracted with carbachol. IMQ was added in
the presence or absence of TTX. Values are
mean percentage of maximal contraction 
SE (n  4).
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not involved. Comparatively, the cyclooxygenase inhibitor
indomethacin reduced the potency of imiquimod-mediated
relaxations without affecting the maximal dilation. This is in
accordance with previous observations (22) and suggests that
ASM-derived prostanoids are involved, but are not crucial, for
imiquimod-mediated effects. Further analysis revealed that the
investigated imiquimod-mediated effects were completely in-
dependent of other conventional pathways of bronchodilation.
CO, which is endogenously produced via the enzyme HO-1
(13), has been shown to dilate guinea pig airways precon-
tracted with histamine in vivo, in a cGMP-dependent manner
(5, 6). In vivo or in vitro inhibition of this pathway, through
blockage of HO-1, cGMP synthase, or PKG, had no effect on
imiquimod-mediated bronchodilation. Similarly, inhibition of
PKA, an important effector molecule for cAMP signaling and
	2-agonist-mediated bronchorelaxation (4), had no effect.
Vasoactive intestinal peptide and NO, mediators derived
from iNANC nerve fibers, are known to potently relax in
guinea pig airways (18, 36). However, in vivo and in vitro
inhibition of NO had no significant effect on imiquimod-
induced relaxation, nor did bilateral vagotomy in vivo, which
prevents reflex-induced bronchodilation (28, 29). In addition,
neuronal blockade with TTX, which prevented EFS-induced
relaxation and, as such, inhibited mediator release from
iNANC fibers, had no effect on imiquimod-induced relaxation
in vitro. These data indicate that neither neuron- or epithelium-
derived mediators, nor CO or cAMP, are critical for imi-
quimod-mediated bronchodilation.
The results in this study demonstrate that imiquimod acts
directly on the ASM and interferes with Ca2 homeostasis.
Exposure of ASM cells to imiquimod resulted in a sharp rise in
[Ca2]i, likely derived from ER stores. Imiquimod subse-
quently, significantly, and concentration-dependently inhibited
histamine-induced mobilization of [Ca2]i. The potencies by
which imiquimod induced [Ca2]i release and inhibited hista-
mine-induced [Ca2]i were similar to in vitro relaxation, sug-
gesting that disruption of Ca2 is of importance for bronchore-
laxation. However, the mechanism by which a rise in [Ca2]i
induces subsequent relaxation is unclear. Previous studies have
demonstrated that imiquimod induces rises in [Ca2]i in sen-
sory neurons (24), and PC12 and F11 cell lines (20), with the
latter study highlighting a role for the inositol triphosphate
(IP3) receptor activation in this process. Contractions by his-
tamine and carbachol, both of which were reversed by imi-
quimod, primarily rely on IP3 signaling and release of ER-
derived Ca2 to induce contraction (25). Imiquimod may
disrupt this pathway either through binding to and blocking the
IP3 receptor (19), or emptying of ER pools, as demonstrated in
this study. Alternatively, it has previously been shown that
localized increases in [Ca2]i in ASM can activate Ca2-
dependent potassium channels (e.g., BKCa), resulting in hyper-































































































































Fig. 5. Imiquimod (IMQ) induces intracellular
calcium mobilization and blocks histamine-
induced calcium mobilization. Isolated air-
way smooth muscle cells were stained with
the Ca2 indicator fluo 4 and exposed to
various compounds, and changes in mean
fluorescence intensity (MFI) were determined
using a BD Accuri C6 flow cytometer. A and
B: cells were exposed to IMQ (100 M) or
histamine (His, 100 M) (arrow). Values are
percent change from baseline (A) or maxi-
mum percent change from baseline (B)  SE.
****P  0.0001 using Student’s t-test (n 
5–15). C: cells were pretreated with thapsi-
gargin (Th; 1 M) or dH2O for 30 min and
exposed to IMQ (100 M, arrow). Values are
MFI or maximum MFI  SE (inset). *P 
0.05 using a Student’s t-test (n  3). D: cells
were exposed to IMQ (100 M) or dH2O
(arrow) and subsequently exposed to Th (1
M, arrow). Values are MFI. E and F: cells
were preincubated with varying concentra-
tions of IMQ for 5 min and subsequently
exposed to His (100 M, arrow). Values are
percentage of maximum vehicle MFI  SE.
**P  0.01, ***P  0.001 using one-way
ANOVA followed by Bonferroni post-hoc
test (n  4–7).
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reported minimal involvement of such channels in imiquimod-
induced relaxation (22), making this less likely. Surprisingly,
despite the sharp rise in [Ca2]i, imiquimod had no effect on
basal airway tone; however, the mechanism underpinning this
dissociation is beyond the scope of this study. It remains to be
determined how imiquimod disrupts Ca2 homeostasis and
thus induces relaxation, but the results suggest it exerts its
effect by acting directly on the ASM.
Imiquimod has previously been shown to upregulate cyto-
kine and chemokine production and alter cell-surface marker
expression on ASM, effects that were evident after 24 h (27).
However, the speed at which imiquimod exerts its effect would
suggest that the effect on ASM does not occur via traditional
TLR-dependent pathways. This is corroborated by the finding
that, in our models, imiquimod-mediated bronchodilation of
guinea pig airways was not dependent on TLR7, as both in
vitro and in vivo administration of the TLR7 antagonist
IRS661 had no effect on imiquimod-mediated bronchodilation.
This was true even when the antagonist was used at in vitro
concentrations 100-fold higher than previously shown to be
effective (27). Additionally, another TLR7 agonist, CL264,
that we and others (7, 19) have shown to be more potent than
imiquimod in terms of TLR7 agonism had no effect on pre-
contracted airways or on histamine-induced Ca2 mobilization
in ASM cells. Indeed, previous studies have demonstrated that
the rise in [Ca2]i following imiquimod administration is
independent of TLR7 (20, 24), substantiating that bronchore-
laxation by imiquimod occurs predominantly independently of
TLR7.
It is likely that the bronchorelaxatory effects of some, but
not all, TLR7 agonists are a consequence of their unique
chemical structures. Imiquimod and R-848, but not CL264,





























































































































Fig. 6. Imiquimod (IMQ) relaxes precon-
tracted guinea pig airways independently of
TLR7 in vitro and in vivo. A and B: guinea
pig airways were precontracted with intrave-
nous histamine in vivo. Aerosolized IMQ (3
mg/kg) was added following intravenous
challenge with IRS661 (0.2 mg/kg). Changes
in maximal Newtonian resistance (RN; B)
and tissue resistance (G; C) were determined.
Values are mean percent change from maxi-
mum resistance. *P  0.05 vs. vehicle using
one-way ANOVA, followed by a Bonferroni
post hoc test (n  4). C: tracheal rings were
precontracted with carbachol (CCH) in vitro.
Increasing doses of IMQ were added cumu-
latively following preincubation with the
TLR7 antagonist IRS661 or vehicle. Percent
change from maximum contraction was de-
termined. Values are percent change from
maximum contraction  SE (n  5). D:
tracheal rings were precontracted with CCH
in vitro. Increasing doses of TLR7 agonists
IMQ, R-848, or CL264 were added cumula-
tively. Percent change from maximum con-
traction was determined. Values are percent
change from maximum contraction  SE (n 
8). E and F: isolated airway smooth muscle
cells were preincubated with varying concen-
trations of CL264 for 5 min and subsequently
exposed to histamine (His; 100 M, arrow).
Values are percentage of maximum vehicle
MFI  SE (n  4–7).
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share a chemical structure known as quinoline. This structure,
not required for TLR7 agonism (39), is also present in other
bronchodilatory compounds with undefined mechanisms of
action, including the bitter taste receptor (TAS2R) agonists
quinine and chloroquine. Quinine and chloroquine relax pre-
contracted mouse, guinea pig, and human airways, at similar
potencies to imiquimod (9, 15, 26, 32) and have been shown to
induce [Ca2]i mobilization (9), as well as inhibit subsequent
calcium release by other agents (14, 30, 35). Indeed, both
quinine and chloroquine have been shown to inhibit [Ca2]i
mobilization primarily by blocking of IP3-IP3 receptor interac-
tions (30, 35), again raising the possibility that imiquimod may
disrupt intracellular IP3-mediated signaling pathways. Other
studies have demonstrated that TLR7 agonists that lack the
quinoline-moiety (loxoribine) do not induce a rise in [Ca2]i
(20, 24), further suggesting that quinoline may be of impor-
tance in TLR7-independent mechanisms of imiquimod. It is
likely that other bronchodilating TLR7 agonists, such as
CL097 and gardiquimod (22), which share similar structural
components, dilate airways through similar mechanisms. Quin-
oline-dependent release and subsequent inhibition of [Ca2]i
responses represent a novel and potential pathway for imi-
quimod-mediated bronchodilation, independent of classical
bronchodilatory mechanisms.
A subset of the data presented in this study can be perceived
as lying in contrast to previously published reports (11, 22). In
the cited studies, bronchodilation occurs at similar potencies
and time frames, as seen in the present study, but instead
occurs via a neuronal, NO-mediated and TLR7-dependent
mechanism. The present findings do not dismiss these reports;
instead, two mechanisms for imiquimod-mediated bronchore-
laxation may conceivably exist, and their relative contribution
is highly dependent on the experimental protocol employed.
For example, the aforementioned studies induced precontrac-
tion mainly through neuronal stimulation, whereas our in vivo
models induced ASM contraction through nonneuronal mech-
anisms. Neuronal NO was likely induced by imiquimod in our
models, but could have been masked by the additional ability
for imiquimod to inhibit histamine-induced Ca2 mobilization
in ASM. The present study supplies an additional and novel
TLR7-independent, ASM-dependent mechanism for imi-
quimod-mediated bronchodilation.
In summary, the present study demonstrates that the proto-
typical TLR7 agonist imiquimod can directly and rapidly relax
precontracted guinea airways in vitro and in vivo. These effects
appear to be independent of the epithelium, neuronal activa-
tion, and conventional pathways of airway relaxation. Instead,
imiquimod acts directly on the ASM and likely causes bron-
chorelaxation through disruption of Ca2 homeostasis. This
effect is independent of TLR7 and may instead be related to the
presence of a quinoline structure. This highlights the potential
use of drugs that combine the effects of quinoline with the
anti-inflammatory action of TLRs in future treatment of in-
flammatory and hyperactive airway disease.
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